Lung Diseases, Interstitial
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Subtype terms (8)
More specific conditions that are subtypes of Lung Diseases, Interstitial in the MeSH hierarchy.
- Alveolitis, Extrinsic Allergic
12 drugs (10 approved, 2 experimental)
- Anti-Glomerular Basement Membrane Disease
5 drugs (1 approved, 4 experimental)
- Granulomatosis with Polyangiitis
37 drugs (30 approved, 7 experimental)
- Histiocytosis, Langerhans-Cell
61 drugs (49 approved, 12 experimental)
- Pneumoconiosis
3 drugs (1 approved, 2 experimental)
- Pulmonary Fibrosis
62 drugs (34 approved, 28 experimental)
- Radiation Pneumonitis
22 drugs (13 approved, 9 experimental)
- Sarcoidosis, Pulmonary
35 drugs (25 approved, 10 experimental)
Drugs by status
Phase 4 trials (15)
Phase 3 trials (17)
Phase 2 trials (42)
- montelukast
- hymecromone
- amitriptyline
- cc-90001
- tanzisertib
- bardoxolone
- duloxetine
- gadoteric acid
- hydroxychloroquine
- xenon-129
- ixazomib
- allogeneic hematopoietic stem cells
- immune globulin (human)
- semaglutide
- abatacept
- trans sodium crocetinate
- alemtuzumab
- uridine
- bortezomib
- l-epigallocatechin
- Yifenidone
- ky1005
- lung stem cells
- mesna
- autologous mesenchymal stem cells
- azithromycin
- budesonide
- thiotepa
- sargramostim
- sodium chloride
- +12 more
Phase 1 trials (12)
Organizations
Organization Involved with Phase 4 Indications (23)
- Actelion
- Roche
- Gilead Sciences
- Pfizer
- Wyeth
- Novartis
- Boehringer Ingelheim
- Vastra Gotaland Region
- Aarhus University
- University of London
- Duke University
- University of South Carolina
- University of Zurich
- Peking University
- University of California, Los Angeles
- Medical University of South Carolina
- Icahn School of Medicine at Mount Sinai
- Jiao Tong University
- University of Gothenburg
- Skanderbog Apotek
- University of Antwerp
- Imperial College London
- National Institute for Tuberculosis and Lung Diseases, Poland
Organization Involved with Phase 3 Indications (40)
- United Therapeutics
- Astellas
- Genentech
- Immtech Pharmaceuticals, Inc
- Shanghai Genomics, Inc.
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- University of Arizona
- University of Pittsburgh
- Henry Ford Health System
- New York University
- Postgraduate Institute of Medical Education and Research
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Tokyo Medical and Dental University
- University of East Anglia
- University of Michigan
- Mayo Clinic
- University of California, San Francisco
- University of Chicago
- University of Cincinnati
- University of Colorado, Denver
- Free University of Amsterdam
- University of Strasbourg
- François Rabelais University
- University of Toulouse
- St. Antonius Hospital, Nieuwegein
- University of Lille
- University of Lyon
- University of North Carolina at Chapel Hill
- University of Nantes
- +10 more
Organization Involved with Phase 2 Indications (38)
- Celgene
- Bristol-Myers Squibb
- Merck
- Merck Serono
- Merck KGaA
- Bayer
- Reata Pharmaceuticals, Inc.
- Regend Therapeutics
- Amarillo Biosciences, Inc.
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
- National Heart, Lung, and Blood Institute (NHLBI)
- A.O. Ospedale Papa Giovanni XXIII
- Huazhong University of Science and Technology
- Brigham and Women's Hospital
- Harvard University
- McGill University
- Medical College of Wisconsin
- Northwestern University
- The Canadian Blood and Marrow Transplant Group
- Texas Tech University
- Thomas Jefferson University
- University of Florida
- University of Alberta
- Marche Polytechnic University
- University of Cambridge
- Belarusian State Medical University
- Southern Medical University
- Ospedale di Circolo
- Sun Yat-Sen University
- Magna Graecia University
- +8 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (5)